One Biosciences

One Biosciences is a Paris-based biotech focused on making single-cell profiling a practical tool for clinical decision-making and drug development. The company has developed an AI-powered platform that rapidly processes standard clinical samples (FFPE/frozen) to deliver actionable, single-cell data, validated across multiple tumor types. Backed by a €15 million Series A financing round in 2025, the company is positioned to partner with pharmaceutical companies and research institutes to improve patient selection, accelerate therapy development, and optimize clinical trials. Its collaborations with leading French cancer centers like Gustave Roussy and Institut Curie underscore its research credibility.

Proprietary AI-powered platform for clinical-grade single-cell profiling from FFPE and frozen tissue samples, delivering clinician-ready reports in under two weeks.

One Biosciences competes with large commercial genomic profiling companies (e.g., Tempus, Guardant) developing single-cell services, specialized single-cell analysis CROs, and academic core facilities. Its differentiation lies in the specific focus on clinical-grade, rapid turnaround from FFPE/frozen samples and AI-driven, clinician-ready reporting.